Abstract
Tumor-associated macrophages can release a vast diversity of growth factors, proteolytic enzymes, cytokines, and inflammatory mediators. Many of these factors are key agents in cancer metastasis. Daintain/AIF-1 is a macrophage-derived inflammatory cytokine which defined a distinct subset of tumor-associated activated macrophages/microglial cells. Previous study demonstrated that daintain/AIF-1 could promote breast cancer proliferation through activating NF-κB/cyclin D1 pathway and facilitate tumor growth. However, the effect of Daintain/AIF-1 on cell migration and cancer metastasis has never been reported. Herein, we used a mimic tumor microenvironment by incubating breast cancer cell lines, MDA-MB-231 and MCF-7 cells, with macrophage-conditioned medium with or without purified daintain/AIF-1 polypeptide to evaluate cell migration. Results indicated that daintain/AIF-1 enhanced the migration of MDA-MB-231 and MCF-7 cells in the manner of TNF-α up-regulation. Further study found that daintain/AIF-1 activates p38 MAPK signaling pathway contributing to up-regulation of TNF-α in MDA-MB-231 and MCF-7 cells. Therefore, this novel daintain/AIF-1-p38-TNF-α pathway and insight into daintain/AIF-1 might have potential benefits in the control of tumor metastasis during cancer therapy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Inflammation is highly correlated with the cancer. Many studies demonstrated that inflammatory mediators are detected in human cancers and experimental cancer models [1–4]. Cancer-associated inflammation promotes the proliferation and survival of malignant cells, stimulates angiogenesis and metastasis, subverts adaptive immunity, and induces the resistant response to hormones and chemotherapy [5]. Macrophages can execute the functions of infiltrate inflammatory cells in solid tumors, which make a significant contribution to tumor microenvironment by secreting a wide range of inflammatory cytokines [5]. Tumor necrosis factor-α (TNF-α) is one of major mediators generated from cancer-related inflammation. Many malignant cells can constitutively produce a small amount of TNF-α [6]. Animal models also provide the evidence that malignant cell-derived TNF-α enhances the growth and metastasis of syngeneic, xenogeneic, and carcinogen-induced tumors in skin, ovary, pancreas, pleural cavity, and bowel [7–11].
Daintain/allograft inflammatory factor-1 (AIF-1) is a macrophage-derived polypeptide. It is an evolutionarily conserved calcium-binding protein with 143 amino acids in cytoplasm [12]. The daintain/AIF-1 gene, located in the major histocompatibility complex (MHC) class III region on chromosome 6p21.3, is densely clustered with genes involved in the inflammatory response, including surface glycoproteins, complement cascade proteins, TNF-α, TNF-β, and nuclear factor-κB (NF-κB) [13]. Daintain/AIF-1 expression is a marker for astrocyte activation in experimental autoimmune neuritis [14] and correlates with inflammation severity in liver allograft rejection [15] and endometriosis [16]. Daintain/AIF-1 expression also modulates vasculopathy by affecting VSMC migration [17].
Our previous study described that high-level expression of daintain/AIF-1 is observed in ductal breast tumor epithelial cells. However, weak or negative expression is detected in the adjacent histologically normal ductal epithelial cells. Daintain/AIF-1 can promote the development of breast cancer by activating NF-κB/cyclin D1 pathway and facilitate tumor growth in nude mice [18].
Inflammatory cells and mediators are key components of tumor microenvironment, and cancer-related inflammation has been proposed to represent the seventh hallmark of cancers [3]. Daintain/AIF-1 defined a distinct subset of tumor-associated activated macrophages/microglial cells [19], and it is crucial for the survival and pro-inflammatory activity of macrophages [20], but the characterization of daintain/AIF-1 in breast tumor microenvironment has not been described. In order to explore the potential properties of daintain/AIF-1, we incubated MDA-MB-231 and MCF-7 cells with macrophage-conditioned media or purified polypeptide daintain/AIF-1, then assessed cell migration. Results indicated that daintain/AIF-1 significantly enhanced the migration of MCF-7 and MDA-MB-231 cells. Meanwhile, the up-regulation of TNF-α was involved in the daintain/AIF-1-induced cell migration, which was confirmed by gene expression profiling analysis. Further study demonstrated that daintain/AIF-1-activated p38 MAPK pathway contributed to TNF-α up-regulation to modulate the migration of breast cancer cells.
Materials and methods
Cell culture
The human monocytic U937 (myelomonocytic) cell line and human breast cancer cell lines, MDA-MB-231 and MCF-7, were purchased from the American Type Tissue Collection (ATCC) and maintained in RPMI 1640 (Life Technologies, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Gaithersburg, MD). Monocytic U937 cells were induced to differentiate by treating with 20 nM PMA (Amresco, OH, USA) for 48 h. Purified daintain/AIF-1 was prepared as described previously [21].
Construction of recombinant plasmids
The recombinant human daintain/AIF-1-pRNAT-H1.1/Shuttle (pRNAT-DT) and siRNA expression vector pRNAT-H1.1/Shuttle (pRNAT) were constructed as described previously in our laboratory [18].
Transfection
The cultured human monocytic U937 cells were washed with phosphate-buffered saline (PBS), and resuspended in complete growth medium at a density of 5 × 107 cells/ml. A total of 25 μg DNA was added to 500 μl of cell suspension in a 0.4-cm electroporation cuvette (BioRad Laboratories, CA, USA). Electroporation was carried out in a BioRad Gene-Pulser electroporation apparatus (BioRad Laboratories, CA, USA) at the condition of 300 V and 950 mF. In order to obtain stable transfected cell line, 600 μg/ml G418 (Amresco, OH, USA) was used to eliminate untransfected cells. Transfectants were pooled and expanded in the complete growth medium supplemented with 300 μg/ml G418.
Western blot
Proteins were extracted using the complete RIPA (Millipore Corporation, MA, USA) buffer. Totally 25 μg protein was loaded and separated on 15% SDS-PAGE gel, and then transferred onto PVDF membrane (Millipore Corporation, MA, USA). The target proteins were probed for daintain/AIF-1 (PTGLAB, Chicago, IL, USA), TNF-α, p38 MAPK, phosphor-p38, and β-actin (Santa Cruz Biotechnology, CA, USA). Antibody reactions were visualized with enhanced chemiluminescence reagents according to the manufacturer’s instructions (Amersham International, Bucks, UK). Optical densities of the bands were measured using the software of Image J.
Conditioned medium
Human monocytic U937 cells were plated at 5 × 105 per well (6-well plate format, Corning Costar, Cambridge, MA, USA) and were then treated with 20 nM PMA overnight. On the next day, the medium was aspirated, and 1 ml of fresh serum-free medium was replaced. Conditioned medium was harvested at 24 h later.
Migration assays
The conditioned medium pre-treated cells at the density of 5 × 105 cells/well were seeded into the upper chambers of an 8-μm pore Costar Transwell (12-well plate format, Corning Costar, Cambridge, MA, USA), with bottom wells containing complete growth medium. After 12 h incubation in the incubator with 5% CO2 at 37°C, the cells migrated to the bottom surface of the porous membrane from the upper chambers were wiped with a cotton swab, fixed with 100% ice-cold methanol and then stained with crystal violet in 0.1 mM borate buffer (pH 9). Migrated cells were quantified by counting in 12 fields under a microscope with a 400× magnification. All experiments were in triplicate.
RT-PCR
Total RNA was prepared using the TRIzol reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s protocol. RT-PCR was performed using a Superscript One-Step RT-PCR kit (Invitrogen). The PCR products were analyzed by electrophoresis on a 2% agarose gel containing ethidium bromide, visualized, and photographed under UV light. The primer sequences and reaction conditions of RT-PCR for TNF-α, TGF-β, EGF, VEGF-A, FGF-2, and β-actin were shown in Table 1.
Statistical analysis
Data were analyzed using the Student t test. The significant difference was considered at P < 0.05.
Results
Daintain/AIF-1 regulate MDA-MB-231 and MCF-7 cells mobility
In order to assess the effect of secreted factors generated by macrophages in breast cancer cells on tumor metastasis, conditioned medium from U937 cells was used for cell migration assay in vitro. Transwell chambers were used to evaluate the migration potential of MDA-MB-231 and MCF-7 cells. The cells in the upper wells of the chamber were seeded in starvation medium, and the bottom wells of the chamber were filled with complete growth medium. In the presence of pre-incubated breast cancer cells with conditioned medium, the average number of the migrated cells in each field was 21 for MDA-MB-231 cells and 20 for MCF-7 cells. In contrast, the average number of the migrated cells in each field was 10 for MDA-MB-231 cells and 10 for MCF-7 cells in the control group without treatment of conditioned medium (Fig. 1a). In both cell lines, the conditioned medium-treated breast cancer cells exhibited a higher migration rate than the control groups (P < 0.05). In addition, compared with the control group, the migration of the cells incubated with purified daintain/AIF-1 polypeptide for 12 h was significantly enhanced (Fig. 1b). Therefore, daintain/AIF-1 may play an important role in cell migration.
Daintain/AIF-1 siRNA/CM decrease cell migration
In order to further characterize the enhancement of daintain/AIF-1-induced migration, the inhibition of daintain/AIF-1 in U937 cells was conducted using stable, vector-based siRNA. Several siRNA constructs based on human daintain/AIF-1 cDNA were cloned into the pRNAT vector. Macrophages were then transfected, stable transfectants were isolated by antibiotic selection, and the resistant cells were pooled. Consequently, conditioned medium of U937 cells with siRNA knockdown of daintain/AIF-1 was prepared. Daintain/AIF-1 expression was verified using western blotting (Fig. 2a). The pRNAT-DT reduced daintain/AIF-1 expression in conditioned medium by an average of 62% (Fig. 2b). MDA-MB-231 and MCF-7 cells pre-incubated with low-expressing daintain/AIF-1-conditioned medium exhibited weak migration (Fig. 2c).
Daintain/AIF-1 up-regulate TNF-α expression
In order to understand the mechanism of daintain/AIF-1-activated migration of breast cancer cells, the expression levels of TNF-α, TGF-β, EGF, FGF-2, and VEGF-A which are involved in cancer metastasis were evaluated by RT-PCR. Compared with the controls, a significant increase of TNF-α expression in MDA-MB-231 cells pre-treated by U937 cell-conditioned medium was observed, whereas no obvious difference in the expression of TGF-β, EGF, FGF-2, and VEGF-A was observed (Fig. 3a). Western blotting analysis showed a significant decrease in TNF-α expression in MDA-MB-231 and MCF-7 cells stimulated by conditioned medium from daintain/AIF-1-siRNA knockdown U937 cells (Fig. 3b, d). In order to further validate the direct regulation of daintain/AIF-1 on TNF-α expression, MDA-MB-231 cells were treated with purified daintain/AIF-1 polypeptide for 12 h. A significantly increased TNF-α expression level in MDA-MB-231 cells was validated by western blot (Fig. 3c, e). Thus, the daintain/AIF-1-regulated TNF-α expression played a critical role in the migration of breast cancer cells.
Daintain/AIF-1 up-regulate TNF-α expression via p38 MAPK activation
To elucidate the signaling pathways that are triggered by daintain/AIF-1 stimulation and that contribute to the cell migration, we initially focused on the MAPK pathway. The p38 MAPK activation in response to daintain/AIF-1 was measured in MDA-MB-231 and MCF-7 cells, respectively. The p38 MAPK was significantly activated by daintain/AIF-1, as shown in Fig. 4a. In contrast, daintain/AIF-1-induced phosphorylation of p38 MAPK was inhibited by SB203580, a specific kinase inhibitor (Fig. 4b). Moreover, the p38 MAPK activity exhibited an obvious contribution to the daintain/AIF-1-induced TNF-α expression in MDA-MB-231 and MCF-7 cells, as shown in Fig. 4b. The cell migration mediated by daintain/AIF-1-p38-TNF-α pathway was further characterized by adding TNF-α neutralizing antibody to the chambers. Compared with the controls, both the blockage of polyantibody and the inhibition of p38 MAPK resulted in less cell migration, as shown in Fig. 4c.
Discussion
Immune cells supply soluble growth and survival factors, matrix remodeling enzymes, reactive oxygen species, and other bioactive molecules that affect the proliferation, angiogenesis, invasion, and metastasis of cancer cells [22–24]. Daintain/AIF-1 is a macrophage-derived polypeptide. Previous studies described that daintain/AIF-1 promotes breast cancer proliferation by activating the NF-κB/cyclin D1 pathway and facilitates breast tumor growth in nude mice [18]. Recent studies have demonstrated that daintain/AIF-1 stimulates the release of cytokines including FGF-2, PDGF, TGF-β, G-CSF, and MCP-1 [14, 20, 25]. However, its roles in tumor microenvironment and its interactions with other cytokines have not been elucidated. In the present study, we demonstrate that daintain/AIF-1 enhances the migration of MDA-MB-231 and MCF-7 cells by augmenting TNF-α expression.
TNF-α is an important inflammatory factor as a master switch in establishing an intricate link between inflammation and cancer. A wide variety of evidences have described the critical role of TNF-α in tumor proliferation, migration, invasion, and angiogenesis [26]. It is well recognized as a regulator of tumor microenvironment. In an ovarian cancer model, TNF-α is observed to be an important component in malignant cell-autonomous network of inflammatory cytokines including stromal cell-derived factors, monocyte chemoattractant protein 1, interleukin-6, macrophage inhibitory factors, and vascular endothelial growth factors [27]. TNF-α in tumor microenvironment may induce epithelial–mesenchymal transition (EMT) of malignant cells in colorectal cancer [9], which provides some reasonable explanations for its capability to increase the metastastic activity of tumor cells [7, 28, 29]. In addition, it is also crucial for the right place, the right time, and the appropriate context for TNF-α production. Thus, restricted production of TNF-α in specific cell types may be a strategy to control its functions [30].
Our previous works show that daintain/AIF-1 can activate NF-κB pathway [18]. Several data in previous reports also exhibit that AIF-1 binds to and participates in F-actin rearrangement, suggesting that AIF-1 may be involved in the cytoskeletal signaling network and contribute to the progression of EMT [17, 31, 32].
Tumor macrophage infiltrating can promote metastasis, which is a normal immune response, but during tumor infiltrating process, macrophages can secrete many kinds of inflammatory factors, lead to malignant tumor and prognosis negative [33–35]. In this study, macrophage-derived inflammatory cytokine daintain/AIF-1 activates p38 MAPK pathway, contributes to the up-regulation of TNF-α, and consequently enhances breast cancer cell migration. Since daintain/AIF-1 could promote breast cancer cell proliferation and enhance cell migration, it is suggested that it play an important role in breast cancer progression. Although the regulatory mechanisms of TNF-α in the migration of breast cancer cells remain elusive, the new role of the daintain/AIF-1-p38-TNF-α pathway and insight into daintain/AIF-1 will benefit to the control of tumor metastasis during cancer therapy.
Abbreviations
- NF-κB:
-
Nuclear factor-κB
- MAPK:
-
Mitogen-activated protein kinase
- TNF-α:
-
Tumor necrosis α
- CM:
-
Conditioned medium
- AIF-1 siRNA:
-
siRNA knockdown of daintain/AIF-1 in U937 cell
- EMT:
-
Epithelial–mesenchymal transition
References
Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211–217. doi:10.1016/j.ccr.2005.02.013
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. doi:10.1038/Nature07205
Sethi G, Sung B, Aggarwal BB (2008) TNF: a master switch for inflammation to cancer. Front Biosci 13:5094–5107
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081. doi:10.1093/carcin/bgp127
Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87:401–406. doi:10.1038/clpt.2009.312
Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J et al (2008) Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 68:1443–1450. doi:10.1158/0008-5472.CAN-07-5704
Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, Orphanidou D, Light RW, Roussos C, Blackwell TS, Kalomenidis I (2007) Tumor necrosis factor-α promotes malignant pleural effusion. Cancer Research 67:9825–9834
Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F (2007) The inflammatory cytokine TNF-α generates an autocrine tumour-promoting network in epithelial ovarian cancer cells. Cancer Res 67:585–592
Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H (1999) Essential role of tumor necrosis factor α (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res 59:4516–4518
Zins K, Abraham D, Sioud M, Aharinejad S (2007) Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 67:1038–1045. doi:10.1158/0008-5472.CAN-06-2295
Deininger MH, Meyermann R, Schluesener HJ (2002) The allograft inflammatory factor-1 family of proteins. FEBS Lett 514:115–121. doi:10.1016/S0014-5793(02)02430-4
Iris FJM, Bougueleret L, Prieur S, Caterina D, Primas G, Perrot V, Jurka J, Rodriguez-Tome P, Claverie JM, Dansset J, Cohen D (1993) Dense Alu clustering and a potential new member of the NF kappa B family within a 90 kilobase HLA class III segment. Nat Genet 3:137–145
Autieri MV, Carbone C, Mu AB (2000) Expression of allograft inflammatory factor-1 is a marker of activated human vascular smooth muscle cells and arterial injury. Arterioscler Thromb Vasc 20:1737–1744
Nagakawaa Y, Nomoto S, Kato Y, Montgomery RA, Williams GM, Klein AS, Zi Sun (2004) Over-expression of AIF-1 in liver allografts and peripheral blood correlates with acute rejection after transplantation in rats. Am J Transpl 2004:1949–1957
Koshiba H, Kitawaki J, Teramoto M, Kitaoka Y, Ishihara H, Obayashi H, Ohta M, Hara H, Adachi T, Honjo H (2005) Expression of allograft inflammatory factor-1 in human eutopic endometrium and endometriosis: possible association with progression of endometriosis. J Clin Endocrinol Metab 90:529–537. doi:10.1210/jc.2004-0871
Autieri MV, Kelemen SE, Wendt KW (2003) AIF-1 is an actin-polymerizing and Rac1-activating protein that promotes vascular smooth muscle cell migration. Circ Res 92:1107–1114. doi:10.1161/01.Res.0000074000.03562.Cc
Liu S, Tan WY, Chen QR, Chen XP, Fu K, Zhao YY, Chen ZW (2008) Daintain/AIF-1 promotes breast cancer proliferation via activation of the NF-kappaB/cyclin D1 pathway and facilitates tumor growth. Cancer Sci 99:952–957. doi:10.1111/j.1349-7006.2008.00787.x
Deininger M, Seid K, Meyermann R, Schluesener HJ (1999) Allograft inflammatory factor-1 (AIF-1) is expressed by activated macrophages and microglia in the vessel walls of human and rat brain tumors and rat autoimmune disease. J Vasc Res 36:187–188
Yang ZF, Ho DW, Lau CK, Lam CT, Lum CT, Poon RTP, Fan ST (2005) Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages. Int Immunol 17:1391–1397. doi:10.1093/intimm/dxh316
Chen ZW, Ahren B, Ostenson CG, Cintra A, Bergman T, Moller C, Fuxe K, Mutt V, Jornvall H, Efendic S (1997) Identification, isolation, and characterization of daintain (allograft inflammatory factor 1), a macrophage polypeptide with effects on insulin secretion and abundantly present in the pancreas of prediabetic BB rats. Proc Natl Acad Sci USA 94:13879–13884
De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate—implications for prostatic carcinogenesis. Am J Pathol 155:1985–1992
Kuper H, Adami HO, Trichopoulos D (2001) Infections as a major preventable cause of human cancer. J Intern Med 249:61–73
Van Kempen LCL, De Visser KE, Coussens LM (2006) Inflammation, proteases and cancer. Eur J Cancer 42:728–734. doi:10.1016/j.ejca.2006.01.004
Chen X, Kelemen SE, Autieri MV (2004) AIF-1 expression modulates proliferation of human vascular smooth muscle cells by autocrine expression of G-CSF. Arterioscler Thromb Vasc Biol 24:1217–1222
Wu Y, Zhou BP (2010) TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 102:639–644. doi:10.1038/sj.bjc.6605530
Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Shakhov AN, Murakami T, Drutskaya LN, Forster I, Clausen BE et al (2005) Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/neutrophils: protective and deleterious effects. Immunity 22:93–104. doi:10.1016/j.immuni.2004.11.016
Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, Mannel DN (1993) Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 177:1391–1398
Bates RC, Mercurio AM (2003) Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 14:1790–1800. doi:10.1091/mbc.E02-09-0583
Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457:U102–U108. doi:10.1038/Nature07623
Hugo HJ, Wafai R, Blick T, Thompson EW, Newgreen DF (2009) Staurosporine augments EGF-mediated EMT in PMC42-LA cells through actin depolymerisation, focal contact size reduction and Snail1 induction—a model for cross-modulation. BMC Cancer 9:235. doi:10.1186/1471-2407-9-235
Yilmaz M, Christofori G (2010) Mechanisms of motility in metastasizing cells. Mol Cancer Res 8:629–642. doi:10.1158/1541-7786.Mcr-10-0139
Estrela-Lima A, Araujo MS, Costa-Neto JM, Teixeira-Carvalho A, Barrouin-Melo SM, Cardoso SV, Martins-Filho OA, Serakides R, Cassali GD (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer 10:256. doi:10.1186/1471-2407-10-256
Chen JJW, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC (2005) Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23:953–964. doi:10.1200/Jco.2005.12.172
Sica A (2010) Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol 32:153–158
Acknowledgments
This work was supported by the National Science Foundation of China (Grants 30370647 and 30470823) and Chinese 863 Program (2002AA214061).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, T., Feng, Z., Jia, S. et al. Daintain/AIF-1 promotes breast cancer cell migration by up-regulated TNF-α via activate p38 MAPK signaling pathway. Breast Cancer Res Treat 131, 891–898 (2012). https://doi.org/10.1007/s10549-011-1519-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-011-1519-x